论文部分内容阅读
目的探讨胃癌患者治疗前后血清可溶性坏死因于受体（ｓＴＮＦ－Ⅰ）水平的临床意义。方法应用酶联免疫吸附测定（ＥＬＩＳＡ）的方法测定了３４例胃癌患者ｓＴＮＦＲ－Ⅰ水平。结果胃癌患者血清ｓＴＮＦＲ－Ⅰ水平明显高于正常人（Ｐ＜０．０１），且与临床分期有关，病情越晚，ｓＴＮＦＲ－Ⅰ水平越高，ｓＴＮＦＲ－Ⅰ水平超过３．００ｎｇ／ｍｌ者预后不良；治疗有效者ｓＴＮＦＲ－Ⅰ均显著下降（Ｐ＜０．０１），２４例治疗后４～８个月再次采血检验，８例无瘤生存者ｓＴＮＦＲ－Ⅰ水平降至正常，其余１６例肿瘤未控制或复发转移者血清ｓＴＮＦＲ－Ⅰ水平升高。结论血清ｓＴＮＦＲ－Ⅰ测定对胃癌疗效观察、病情监测及预后判断有重要意义。
Objective To investigate the clinical significance of serum soluble necrosis due to receptor (sTNF-I) levels in patients with gastric cancer. Methods sTNFR-I levels were determined in 34 patients with gastric cancer by enzyme-linked immunosorbent assay (ELISA). Results The serum level of sTNFR-I in gastric cancer patients was significantly higher than that in normal controls (P<0.01), and was related to clinical stage. The later the disease, the higher the level of sTNFR-I, and the sTNFR-I level was over 3.00 ng/ml. Adversely, sTNFR-I was significantly decreased in patients with effective treatment (P<0.01). 24 patients were re-examined 4 to 8 months after treatment. sTNFR-I levels were reduced to normal in 8 patients with tumor-free survival, and the other 16 tumors. Serum sTNFR-I levels were elevated in uncontrolled or recurrent metastasis. Conclusion Serum sTNFR-I assay has important significance for the observation of gastric cancer, disease monitoring and prognosis.